Related Experiment Video
Updated: Apr 3, 2026

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
Published on: October 18, 2013
[Limitations, pitfalls and perspectives of diagnostic massive parallel sequencing efforts in oncology]
W Weichert1,2
1Institut für Pathologie, Universitätsklinikum Heidelberg, Universität Heidelberg und Nationales Centrum für Tumorerkrankungen (NCT), Im Neuenheimer Feld 224, 69120, Heidelberg, Deutschland. wilko.weichert@tum.de.
Abstract:
Tremendous developments in the field of predictive biomarkers for treatment with targeted drugs together with impressive advances in the field of massive parallel sequencing (MPS) technologies have revolutionized the concept of personalized medicine in oncology. Although these developments hold great promise for our patients, we must be aware of important limitations and pitfalls in routine diagnostic high throughput sequencing. This includes scientific, technical, social but also economic aspects which have to be addressed. In this article, the respective topics are systematically analyzed and considerations and possible solutions for the successful implementation of MPS technologies into patient care are discussed.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016